Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V(1A) and V2 receptor antagonist, in dogs

European Journal of Pharmacology

Volumn 321, Issue 2, 1997, Pages 225-230

  Yatsu, Takeyuki ^a   Tomura, Yuichi ^a   Tahara, Atsuo ^a   Wada, Koh Ichi ^a   Tsukada, Junko ^a   Uchida, Wataru ^a   Tanaka, Akihiro ^a   Takenaka, Toichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Non peptide antagonist; Vasopressin; Vasopressin V(1A) receptor; Vasopressin V2 receptor; YM087

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; CONIVAPTAN; FUROSEMIDE; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSOR RESPONSE; DOG; DOSE RESPONSE; DRUG RECEPTOR BINDING; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICTURITION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; URINE OSMOLALITY;

ANIMALS; BENZAZEPINES; DOGS; FEMALE; MALE; RADIOLIGAND ASSAY; RECEPTORS, VASOPRESSIN;

EID: 0031039813     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00940-5     Document Type: Article

References (18)

1. Bouby, N., S. Bachmann, D. Bichet and L. Bankir, 1990, Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat, Am. J. Physiol. 258, F973.
2. Chen, J.-L.J., D.F. Babcock and H.A. Dardy, 1978, Norepinephrine, vasopressin, glucagon, and A23187 induce efflux of calcium from an exchangeable pool in isolated rat hepatocytes, Proc. Natl. Acad. Sci. USA 75, 2234.
3. DiTullio, N.W., L.B. Kinter and B.L. Storer, 1985, Pharmacological characterization of vasopressin aggregation response of human platelets, Thromb. Res. 40, 425.
4. Fox, A.W., 1988, Vascular vasopressin receptors, Gen. Pharmacol. 19, 639.
5. Laszlo, F.A., F. Laszlo and D. De Wied, 1991, Pharmacology and clinical perspectives of vasopressin antagonist, Pharmacol. Rev. 43, 73.
6. Manning, M. and W.H. Sawyer, 1989, Discovery, development, and some uses of vasopressin and oxytocin antagonists, J. Lab. Clin. Med. 114, 617.
7. Michel, R.H., C.J. Kirk and M.M. Billah, 1979, Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin, Biochem. Soc. Trans. 7, 861.
8. Naitoh, M., H. Suzuki, M. Murakami, A. Matsumoto, K. Arakawa, A. Ichihara, H. Nakamoto, K. Oka, Y. Yamamura and T. Saruta, 1994, Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs, Am. J. Physiol. 267, H2245.
9. Ohnishi, A., Y. Orita, R. Okahara, H. Fujihara, T. Inoue, Y. Yamamura, Y. Yabuuchi and T. Tanaka, 1993, Potent aquaretic agent, a novel nonpepitide selective vasopressin 2 antagonist (OPC-31260) in men, J. Clin. Invest. 92, 2653.
10. 2 antagonist in men, J. Pharmacol. Exp. Ther. 272, 546.
11. 2 receptor antagonists on progressive renal failure in rats, Clin. Sci. 86, 399.
12. Pettibone, D.J., C.J. Woyden and J.A. Totaro, 1990, Identification of functional oxytocin receptors in lactating rat mammary gland in vitro, Eur. J. Pharmacol. 188, 235.
13. 2 antagonist OPC-31260 in hydropenic humans, Kidney Int. 48, 220.
14. Thibonnier, M. and J.M. Roberts, 1985, Characterization of human platelet vasopressin receptors, J. Clin. Invest 76, 1857.
15. Vanderwel, M., D.S. Lum and R.J. Haslam, 1983, Vasopressin inhibits the adenylate cyclase activity of human platelet particular fraction through V1-receptors, FEES Lett. 164, 340.
16. Vittet, D., A. Rondot, B. Cantau, J.M. Launay and C. Chevillard, 1986, Nature and properties of human platelet vasopressin receptors, Biochem. J. 223, 631.
17. 1 receptor antagonist, Science 252, 572.
18. 2 receptor antagonist, Br. J. Pharmacol. 105, 787.